Dr. Christopher D. Earl is President and CEO of BIO Ventures for Global Health, a not-for-profit organization dedicated to increasing the pipeline of innovative medicines for diseases of the developing world. BVGH is increasing access to novel vaccines, drugs and diagnostics by creating market-based incentives for industry commitment, catalyzing biotech innovation, and promoting public and private sector initiatives. Dr. Earl previously served as Managing Director of the Perseus-Soros BioPharmaceutical Fund, L.P., a leading investor in later-stage life science companies, where he managed investments in biopharmaceutical companies and served as a director on portfolio company boards. Earlier in his career, Dr. Earl was President and CEO of Avitech Diagnostics, Inc., and a General Partner of Plant Resources Venture Funds. Dr. Earl serves on the boards of Replidyne, Inc. and Asuragen, Inc., and on the Board of Governing Trustees of the Jackson Laboratory. Dr. Earl received a Bachelor’s Degree in Biology from the University of Pennsylvania, and a Doctorate in Cellular and Developmental Biology from Harvard University.